KCPG
PCRX icon

Kavar Capital Partners Group’s Pacira BioSciences PCRX Stock Holding History

Kavar Capital Partners Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-8
Closed – – 305
2015
Q4 		$0 Buy
+8
New +$453 ﹤0.01% 512
2015
Q3 		– Sell
-10
Closed – – 519
2015
Q2 		$0 Buy
+10
New +$788 ﹤0.01% 530

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kavar Capital Partners Group's PCRX Position: Q1 2016 in Review

Kavar Capital Partners Group sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 8 shares.

Kavar Capital Partners Group first reported a position in PCRX in Q2 2015 and held it in 2 quarters. The position peaked at $0 in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

  • Kavar Capital Partners Group reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
  • Kavar Capital Partners Group sold 8 Pacira BioSciences shares in Q1 2016.
  • Kavar Capital Partners Group first reported a position in Pacira BioSciences in Q2 2015 and held it in 2 quarters.
  • Kavar Capital Partners Group's Pacira BioSciences position peaked at $0 in Q4 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Kavar Capital Partners Group's 13F filing for Q1 2016, filed 13 May 2019.